This study involves receiving blinatumomab after high-dose melphalan and autologous stem cell transplant (ASCT) for multiple myeloma. The main purpose of this study is to:
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.